FDA approve over 100 drugs in 2008

Share this article:
The FDA's drug safety director, Gerald Dal Pan, has given an update on progress to date, including a tally of 34 new postmarket studies or clinical trials ordered last year.

Addressing a Food & Drug Law Institute conference in January, Dal Pan called 2008 a particularly “eventful year,” with important organizational and management changes and over 100 approvals of drug and biologic applications and efficacy supplements during the period from March through November. 

Twenty-four of the post-market safety studies or trials ordered were associated with initial NDA or BLA approvals, and the remaining 10 were for already-approved products, based on “new safety information,” or newly-identified “serious risks.”

Dal Pan indicated that changes were required for seven safety labels, including changes applicable to some drug classes, and a total of 21 risk evaluation and mitigation strategies (REMS) were approved. The latter included 16 actions in which the strategies consisted of Medication Guides (MedGuides) only, and five actions in which the required REMS included other elements to assure safe use of a product and/or a communication plan for educating health care providers and patients in safe use of a product.

A more detailed discussion of REMS—including the FDA's interpretation of relevant statutory provisions and authorities, and early steps toward implementation—was provided by Dal Pan's acting director of the Division of Risk Management Claudia Karwoski.

She noted that REMS are tailored to address safety issues associated with specific, individual products, and thus they may take many different forms. “The only common element required of all REMS is a timetable for assessing their effectiveness,” she said. 

In some cases, sponsors may believe that adherence to practices specified in a MedGuide are sufficient to constitute a REMS; but in all such cases, when applying to the agency, sponsors should include a description of how MedGuides will be distributed, Kawolski said. In cases where FDA requires REMS to include a communication plan, the target audiences must be described, and any educational materials appended to the REMS proposal.

According to Karwoski, examples of some elements of REMS that may be considered by sponsors to assure safe use would include: requiring healthcare providers and pharmacists to have special training or experience or special certifications; requiring that the drug be dispensed only in certain healthcare settings; and requiring that each patient taking the drug be enrolled in a registry, or subject to blood tests or other periodic monitoring.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.